Valneva's Chikungunya Vaccine Shows Durability After Five Years

Valneva SE has reported sustained success with its chikungunya vaccine candidate, IXCHIQ®. Five years post-vaccination, 94% of participants maintained effective antibody levels. Importantly, similar results were observed across different age groups, including those 65 and older.

This new data supports the vaccine's potential for long-term protection, critical in regions where chikungunya outbreaks are unpredictable. For individuals in endemic areas with limited healthcare access, IXCHIQ® offers a significant public health benefit. The study, backed by CEPI and the EU, continues tracking participants for up to ten years to evaluate lasting immune responses.

IXCHIQ® is also undergoing post-marketing studies, including a large-scale vaccination pilot in Brazil. Nearly 80,000 individuals participated, contributing valuable data on the vaccine's effectiveness and safety, bolstering its public health significance.